EU Actions ‘Will Weaken IP And Undermine Innovation’
PhRMA Attacks Commission’s Pharmaceutical Strategy
In its 2022 “Special 301” submission, US pharmaceutical industry group PhRMA says that EU data protections and other incentives for innovative R&D are under threat, echoing concerns already expressed by European industry bodies.
You may also be interested in...
Compulsory licensing in Russia, domestic production measures in Turkey, and clinical trial requirements for Germany’s pricing and reimbursement process come under fire in PhRMA's “Special 301” report to the US Trade Representative.
PhRMA wants the UK to be placed on the US Trade Representative’s “Watch List” over issues such as the supplementary protection certificate waiver and delays in access to new drugs caused by “overlapping” cost-containment measures.
From Innovation Mindsets To Incentives And COVID-19 Lessons: How EU Pharma Legislation Should Evolve
If the EU wants to become a more competitive space for innovation it can take a few lessons from both the US and the COVID-10 pandemic, say European pharma industry representatives. Fostering better communication between regulators and companies is just one example.